Results of successful application of radiofrequency ablation in the treatment of hepatocellular carcinoma (HCC)



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

оne of the methods of surgical treatment of hepatocellular carcinoma (HCC) is local destruction (energy ablation) of the tumor, which is performed on patients with HCC in stage BCLC 0 (solitary tumor up to 2 cm in diameter), in stage BCLC A (three tumors up to 3 cm in diameter) when surgical treatment (liver resection or liver transplantation) is impossible.

Full Text

Restricted Access

About the authors

Milyausha Kamalova

P.A.Herzen Moscow Research Oncological Institute - Branch of the Federal State Budgetary Institution "National Medical Research Center of Radiology" of the Ministry of Health of Russia, Moscow, Russia

Author for correspondence.
Email: milyausha.kamalova.97@mail.ru
ORCID iD: 0000-0003-0495-8585

postgraduate student of the abdominal surgery department of the P.A. Herzen Moscow Oncology Research Institute

Russian Federation, 2nd Botkinsky Prospekt, 3, Moscow, 125284

Vladimir Sergeevich Trifanov

P.A.Herzen Moscow Research Oncological Institute - Branch of the Federal State Budgetary Institution "National Medical Research Center of Radiology" of the Ministry of Health of Russia, Moscow, Russia

Email: trifan1975@yandex.ru
ORCID iD: 0000-0003-1879-6978

Head of the Center for Abdominal Surgery, MD, Surgeon, Leading Researcher of the Abdominal Surgery Department

Russian Federation, 2nd Botkinsky Prospekt, 3, Moscow, 125284

Marina Dmitrievna Budurova

P.A.Herzen Moscow Research Oncological Institute - Branch of the Federal State Budgetary Institution "National Medical Research Center of Radiology" of the Ministry of Health of Russia, Moscow, Russia

Email: m.budurova@rambler.ru
ORCID iD: 0000-0003-1391-0516

Leading researcher of the abdominal surgery department, Doctor of Medical Sciences, Professor of the Department of Oncology of the Faculty of Continuing Professional Education of the Federal State Budgetary Educational Institution of Higher Education “Moscow State University of Medicine and Dentistry named after A.I. Evdokimov” of the Ministry of Health of the Russian Federation

2nd Botkinsky Prospekt, 3, Moscow, 125284

Maria Andreevna Chernichenko

P.A.Herzen Moscow Research Oncological Institute - Branch of the Federal State Budgetary Institution "National Medical Research Center of Radiology" of the Ministry of Health of Russia, Moscow, Russia

Email: mashustic04@mail.ru
ORCID iD: 0000-0002-2427-9232

Oncologist of the abdominal surgical department, PhD

Russian Federation, 2nd Botkinsky Prospekt, 3, Moscow, 125284

Nikolay Alexandrovich Grishin

P.A.Herzen Moscow Research Oncological Institute - Branch of the Federal State Budgetary Institution "National Medical Research Center of Radiology" of the Ministry of Health of Russia, Moscow, Russia

Email: grishinlap@mail.ru
ORCID iD: 0000-0003-1703-9115

Head of the Center for Abdominal Surgery, MD, Surgeon, Leading Researcher of the Abdominal Surgery Department

Russian Federation, 2nd Botkinsky Prospekt, 3, Moscow, 125284

References

  1. Salgia R., & Mendiratta V. The Multidisciplinary Management of Hepatocellular Carcinoma // Clinical liver disease –2021 – Vol. 17No. 6 – P. 405–408. https://doi.org/10.1002/cld. 1068.
  2. Rahib L., Wehner M. R., Matrisian L. M., Nead K. T. Estimated Projection of US Cancer Incidence and Death to 2040 // JAMA Netw Open. 2021 – Vol. 4 No. 4: e214708. doi: 10.1001/jamanetworkopen. 2021.4708. PMID: 33825840; PMCID: PMC8027914.
  3. Malignant neoplasms in Russia in 2022 (incidence and mortality) / Ed. A.D. Kaprin, V.V. Starinsky, A.O. Shakhzadova, I.V. Lisichnikova - M.: MNIOI im. P. A. Gertsen. - branch of the Federal State Budgetary Institution "NMITs of Radiology" of the Ministry of Health of the Russian Federation, 2023. - ill. - 275 p. ISBN 978-5-85502-290-2.
  4. Breder V.V., Bazin I.S., Balakhnin P. . V., Virshke E.R., Kosyrev V.Yu., Ledin E.V. et al. Practical recommendations for drug treatment of patients with malignant tumors of the liver and biliary system. RUSSCO Practice Guidelines, Part 1. Malignancies, 2023 (vol. 13), #3s2, pp. 494–538.
  5. N'Kontchou G, Mahamoudi A, Aout M, et al. Radiofrequency ablation of hepatocellular carcinoma: long-term results and prognostic factors in 235 patients with liver cirrhosis from Western countries. Hepatology 2009; 50:1475–83.
  6. Shiina S, Tateishi R, Arano T, Uchino K, Enooku K, Nakagawa H, Asaoka Y, Sato T, Masuzaki R, Kondo Y , Goto T, Yoshida H, Omata M, Koike K. Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol. 2012 Apr;107(4):569-77; quiz 578. doi: 10.1038/ajg.2011.425. Epub 2011 Dec 13. PMID: 22158026; PMCID: PMC3321437.
  7. Kim YS, Lim HK, Rhim H, Lee MW, Choi D, Lee WJ, Paik SW, Koh KC, Lee JH, Choi MS, Gwak GY, Yoo BC. Ten-year outcomes of percutaneous radiofrequency ablation as first-line therapy of early hepatocellular carcinoma: analysis of prognostic factors. J Hepatol. 2013 Jan;58(1):89-97. doi: 10.1016/j.jhep.2012.09.020. Epub 2012 Sep 27. PMID: 23023009.
  8. Yang W, Yan K, Goldberg SN, Ahmed M, Lee JC, Wu W, Zhang ZY, Wang S, Chen MH. Ten-year survival of hepatocellular carcinoma patients undergoing radiofrequency ablation as a first-line treatment. World J Gastroenterol. 2016 Mar 14;22(10):2993-3005. doi: 10.3748/wjg.v22.i10.2993. PMID: 26973395; PMCID: PMC4779922.
  9. Seror O, N'Kontchou G, Nault JC, Rabahi Y, Nahon P, Ganne-Carrié N, Grando V, Zentar N, Beaugrand M, Trinchet JC, Diallo A, Sellier N. Hepatocellular Carcinoma within Milan Criteria: No- Touch Multibipolar Radiofrequency Ablation for Treatment-Long-term Results. Radiology. 2016 Aug;280(2):611-21. doi: 10.1148/radiol.2016150743. Epub 2016 Mar 24. Erratum in: Radiology. 2016 Sep;280(3):981. doi: 10.1148/radiol.2016164017. PMID: 27010381.
  10. Weitz, Ilene C.1; Liebman, Howard A. M.D. Des-γ-carboxy (abnormal) prothrombin and hepatocellular carcinoma: A critical review. doi: 10.1002/hep.1840180434, Hepatology. 18(4):990-997, October 1993.
  11. Lencioni, R. (2010), Loco-regional treatment of hepatocellular carcinoma. Hepatology, 52: 762-773. https://doi.org/10.1002/hep.23725.
  12. Tiong L., Maddern G.J. Systematic review and meta-analysis of survival and disease recurrence after radiofrequency ablation for hepatocellular carcinoma // Br. J. Surg. 2011. Vol. 98, No. 9. P. 1210–1224.
  13. Germani G. et al. Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: A meta-analysis // J. Hepatol. 2010. Vol. 52, no. 3. P. 380–388.
  14. Zhu Z.X. et al. Radiofrequency ablation with or without ethanol injection for hepatocellular carcinoma: a systematic review and meta-analysis. // Minerva Med. 2016. Vol. 107, No. 6. P. 381–391.
  15. Wang W., Shi J., Xie W.-F. Transarterial chemoembolization in combination with percutaneous ablation therapy in unresectable hepatocellular carcinoma: a meta-analysis // Liver Int. 2010. Vol. 30, No. 5. P. 741–749.
  16. Ni J. et al. Transarterial chemoembolization combined with percutaneous radiofrequency ablation versus TACE and PRFA monotherapy in the treatment for hepatocellular carcinoma: a meta-analysis // J. Cancer Res. Clin. Oncol. 2013. Vol. 139, No. 4. P. 653–659.
  17. Ni J. et al. Transarterial chemoembolization combined with percutaneous radiofrequency ablation versus TACE and PRFA monotherapy in the treatment for hepatocellular carcinoma: a meta-analysis // J. Cancer Res. Clin. Oncol. 2013. Vol. 139, No. 4. P. 653–659.
  18. Tian G. et al. Comparative efficacy of treatment strategies for hepatocellular carcinoma: systematic review and network meta-analysis // BMJ Open. 2018. Vol. 8, No. 10. P. e021269.
  19. Ross, W.B. Cryotherapy of liver tumors - a practical guide/ W.B. Ross, M.Horton, P. Bertolino// HPB Surg. - 1995. - Vol. 8. – P. 167 -173.
  20. Ionkin, D.A. History of the development of radiofrequency ablation as a surgical technique / D.A. Ionkin, V.A. Vishnevsky, A.V. Zhao // High-tech medicine. - 2014. - T. 1, No. 2. - P. 4-11.
  21. N'Kontchou G, Mahamoudi A, Aout M, et al. Radiofrequency ablation of hepatocellular carcinoma: long-term results and prognostic factors in 235 Western patients with cirrhosis. Hepatology 2009;50:1475-83.
  22. Shiina S, Tateishi R, Arano T, et al. Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol 2012;107:569-77.
  23. Kim YS, Lim HK, Rhim H, et al. Ten-year outcomes of percutaneous radiofrequency ablation as first-line therapy of early hepatocellular carcinoma: analysis of prognostic factors. J Hepatol 2013;58:89-97.
  24. Lee DH, Lee JM, Lee JY, et al. Radiofrequency ablation of hepatocellular carcinoma as first-line treatment: long-term results and prognostic factors in 162 patients with cirrhosis. Radiology 2014;270:900-9.
  25. Yang W, Yan K, Goldberg SN, et al. Ten-year survival of hepatocellular carcinoma patients undergoing radiofrequency ablation as a first-line treatment. World J Gastroenterol 2016;22:2993-3005.
  26. Seror O, N’Kontchou G, Nault JC, et al. Hepatocellular carcinoma within Milan criteria: no-touch multibipolar radiofrequency ablation for treatment-long-term results. Radiology 2016;280:611-21.
  27. S.M. Lin, C.J. Lin, C.C. Lin, C.W. Hsu, Y.C. Chen. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4 cm/ Gastroenterology, 127 (2004), pp. 1714-1723.
  28. R. Lencioni, H.P. Allgaier, D. Cioni, M. Olschewski, P. Deibert, L. Crocetti, et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology, 228 (2003), pp. 235-240.
  29. Brunello, A. Veltri, P. Carucci, E. Pagano, G. Ciccone, P. Moretto, et al.Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: a randomized controlled trial. Scand J Gastroenterol, 43 (2008), pp. 727-735.
  30. R. Lencioni, D. Cioni, L. Crocetti, C. Franchini, C.D. Pina, J. Lera, et al. Early-stage hepatocellular carcinoma in cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation Radiology, 234 (2005), pp. 961-996.
  31. M. Omata, R. Tateishi, H. Yoshida, S. Shiina. Treatment of hepatocellular carcinoma by percutaneous tumor ablation methods: ethanol injection therapy and radiofrequency ablation. Gastroenterology, 127 (2004), pp. S159-S166.
  32. T. Livraghi, F. Meloni, M. Di Stasi, E. Rolle, L. Solbiati, C. Tinelli, et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice? Hepatology, 47 (2008), pp. 82-89.
  33. M. Sala, J.M. Llovet, R. Vilana, L. Bianchi, M. Solé, C. Ayuso, et al. Barcelona Clínic Liver Cancer Group. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology, 40 (2004), pp. 1352-1360.
  34. J. Huang, L. Yan, Z. Cheng, H. Wu, L. Du, J. Wang, et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria Ann Surg, 252 (2010), pp. 903-912.
  35. M.S. Chen, J.Q. Li, Y. Zheng, R.P. Guo, H.H. Liang, Y.Q. Zhang, et al.A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma.Ann Surg, 243 (2006), pp. 321-328.
  36. J. Huang, L. Yan, Z. Cheng, H. Wu, L. Du, J. Wang, et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria Ann Surg, 252 (2010), pp. 903-912.
  37. D.S. Lu, N.C. Yu, S.S. Raman, P. Limanond, C. Lassman, K. Murray, et al.Radiofrequency ablation of hepatocellular carcinoma: treatment success as defined by histologic examination of the explanted liver.
  38. Y. Komorizono, M. Oketani, K. Sako, N. Yamasaki, T. Shibatou, M. Maeda, et al.Risk factors for local recurrence of small hepatocellular carcinoma tumors after a single session, single application of percutaneous radiofrequency ablation Cancer, 97 (2003), pp. 1253-1262.
  39. J. Imamura, R. Tateishi, S. Shiina, E. Goto, T. Sato, T. Ohki, et al.Neoplastic seeding after radiofrequency ablation for hepatocellular carcinoma Am J Gastroenterol, 103 (2008), pp. 3057-3062.
  40. J.M. Llovet, R. Vilana, C. Brú, L. Bianchi, J.M. Salmeron, L. Boix, et al.Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma Hepatology, 33 (2001), pp. 1124-1129,
  41. T. Teratani, H. Yoshida, S. Shiina, T. Teratani, S. Obi, N. Yamashiki, et al.Radiofrequency ablation for hepatocellular carcinoma in so-called high-risk locations Hepatology, 43 (2006), pp. 1101-1108.
  42. Вишневский, В.А. Осложнения радиочастотной термоаблации злокачественных новообразований печени/ В.А.Вишневский, А.В.Федоров, Д.А.Ионкин, О.И Жаворонкова, А.Б. Шуракова, Н.А.Курушкина // Хирургия. – 2010. - № 2. - С. 18-29.
  43. Finelli, A. Cryotherapy and radiofrequency ablation: pathophysiologic basis and laboratory studies/ A. Finelli, J.C. Rewcastle, M.A. Jewett// Curr Opin Urol. -2003. – Vol. 13. – P. 187–191.
  44. Fiorentini, G. Multidisciplinary approach of colorectal cancer liver metastases/ G. Fiorentini, D. Sarti, C. Aliberti, R. Carandina, A. Mambrini, S.Guadagni// World J Clin Oncol. – 2017. – Vol. 8 (3). – Р. 190-202.
  45. D.R. Wahl, M.H. Stenmark, Y. Tao, E.L. Pollom, E.M. Caoili, T.S. Lawrence, et al. Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma.J Clin Oncol, 34 (2016), pp. 452-459.
  46. S. Shiina, R. Tateishi, T. Arano, K. Uchino, K. Enooku, H. Nakagawa, et al. Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors Am J Gastroenterol, 107 (2012), pp. 569-577quiz 578.
  47. Izumi N, Hasegawa K, Nishioka Y, Takayama T, Yamanaka N, Kudo M, et al. A multicenter randomized controlled trial to evaluate the efficacy of surgery vs. radiofrequency ablation for small hepatocellular carcinoma (SURF trial). Journal of Clinical Oncology. 2019; 37:4002.
  48. Doyle A, Gorgen A, Muaddi H, Aravinthan AD, Issachar A, Mironov O, et al. Outcomes of radiofrequency ablation as first-line therapy for hepatocellular carcinoma less than 3cm in potentially transplantable patients. J Hepatol. 2019; 70:866–873.
  49. Singal, Amit G.; Llovet, Josep M.; Yarchoan, Mark; Mehta, Neil; Heimbach, Julie K.; Dawson, Laura A.; Jou, Janice H.; Kulik, Laura M; Agopian, Vatche G.; Marrero, Jorge A.; Mendiratta-Lala, Mishal; Brown, Daniel B.; Rilling, William S.; Goyal, Lipika; Wei, Alice C.; Taddei, Tamar H. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology 78(6):p 1922-1965, December 2023. | doi: 10.1097/HEP.0000000000000466.
  50. Tiong L., Maddern G.J. Systematic review and meta-analysis of survival and disease recurrence after radiofrequency ablation for hepatocellular carcinoma // Br. J. Surg. 2011. Vol. 98, № 9. P. 1210–1224.
  51. Germani G. et al. Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: A meta-analysis // J. Hepatol. 2010. Vol. 52, №3. P. 380–388.
  52. Долгушин Б.И., Патютко Ю.И., Шолохов В.Н., Косырев В.Ю. Радиочастотная термоаблация опухолей печени / под.ред. М.И. Давыдова. М.: Практическая медицина, 2007. 192 с.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) Eco-Vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ПИ № ФС 77 - 86496 от 11.12.2023 г. 
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ЭЛ № ФС 77 - 80673 от 23.03.2021 г.